DelfaGLP-1 Atlas

← Trials/Trial dossier/NCT01818648

WithdrawnPhase 4

Exenatide on GI Motor Function and Permeability in Short Bowel Syndrome

Acute Effects of a Glucagon-like Peptide 1 Analog, Exenatide, on Gastrointestinal Motor Function and Permeability in Patients With Short Bowel Syndrome on Home Parenteral Nutrition

Lead sponsor

Mayo Clinic

Asset

Exenatide

Subcutaneous · GLP-1 agonist

Listed sites

0

Recruiting sites

—

Enrollment

—

actual

Study population

Gastrointestinal (gastroparesis / short bowel / pancreatitis)

Key I/E criterion

—

Primary endpoint

•24hr Gastrointestinal and Colonic Transit before and after Exenatide

Identifiers

Registered as

NCT IDNCT01818648
Org study ID12-008505

Timeline

Milestones

Study first posted2013-03-26estimated
Last update posted2014-01-14estimated
Study start2013-03 (month precision)
Primary completion2014-01actual (month precision)
Study completion2014-01actual (month precision)

Assets

Investigational agents

Exenatide

Study populations

Who this study enrolls

Gastrointestinal (gastroparesis / short bowel / pancreatitis)

Eligibility

Who can enroll

Minimum age18 Years
Maximum age85 Years
SexAll
Healthy volunteersNot accepted

Eligibility criteria

Patients with short bowel syndrome, between the ages of 18-85 who are dependent on parenteral nutrition for at least a year and are being closely followed by the Mayo Clinic Home Parenteral Nutrition Program (HPN) with at least one multisystem evaluation a year.

Endpoints (4)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Other clinical outcomes
2
Other (unclassified)
2

Other clinical outcomes

2 endpoints
Primary/protocol endpoint

Change in 24hr Gastrointestinal and Colonic Transit before and after Exenatide vs placebo

Time frame:In both arms participants will undergo GI transit measurements on 2 seperate occasions for a total of 24 hours, with a wash out period of 48 hours in between transit studies.

change from baseline, improvement

Other/protocol endpoint

Change in 24hr Stool Weight before and after administration of Exenatide vs placebo

Time frame:In both arms participants will collect stool weight for 24 hours in 2 seperate occasions with a wash out period of 48 hours in between collections.

change from baseline, improvement

Other (unclassified)

2 endpoints
Secondary/protocol endpoint/low confidence

Change in 24hr Intestinal Permeability before and after administration of Exenatide vs placebo

Time frame:In both arms participants will undergo intestinal permeability measurements on 2 seperate occasions for 24 hours,with a wash out period of 48 hours in between permeability studies. .

change from baseline, improvement

Other/protocol endpoint/low confidence

Change in 24hr Urine Volume before and after administration of Exenatide vs placebo

Time frame:In both arms participants will collect urine volume for 24 hours in 2 seperate occasions with a wash out period of 48 hours in between collections.

change from baseline, descriptive

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 1, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.